Immutep said Friday that partner GlaxoSmithKline ended a Phase II study investigating GSK2831781 in patients with active ulcerative colitis. According to Immutep, the trial was stopped after a planned interim analysis of data conducted in consultation with a data review committee.
GlaxoSmithKline will undertake further analyses of the efficacy and safety data, whilst also evaluating the biology, before determining next steps for the programme, Immutep noted. GSK2831781 has also been investigated in a Phase I study in patients with psoriasis, which showed preliminary evidence of clinical efficacy.
GSK2831781 is a depleting anti-LAG antibody that was derived from IMP731 and licensed to GlaxoSmithKline in 2010. Immutep noted that the companies' collaboration currently remains in place.
To read more Top Story articles, click here.